SaMD(Software as a Medical Device) 시장 예측(2026-2032년)

The Software as a Medical Device Market is projected to grow by USD 10.47 billion at a CAGR of 7.45% by 2032.

Software as a Medical Device Executive Summary

Software as a Medical Device (SaMD) is reshaping healthcare delivery by enabling software-driven diagnosis, monitoring, clinical decision support, disease management, and personalized therapy without being part of a physical medical device. The category is increasingly important as health systems adopt digital health platforms, remote patient monitoring, mobile health applications, cloud-based clinical workflows, and connected care models. Regulatory bodies define SaMD by its intended medical purpose, making clinical validity, cybersecurity, usability, interoperability, and post-market performance central to product success. Demand is supported by rising chronic disease burden, expanding telehealth use, growing clinical data availability, and the need for scalable tools that improve access to care while supporting evidence-based decisions. As hospitals, payers, life sciences organizations, and digital health developers advance software-led care pathways, SaMD is moving from standalone applications toward integrated, AI-enabled, interoperable ecosystems that must meet rigorous standards for safety, effectiveness, transparency, and lifecycle management.

Transformative Shifts in the SaMD Landscape

The SaMD landscape is undergoing transformative shifts as healthcare organizations move from episodic, facility-based care toward continuous, data-driven, and patient-centered models. Cloud deployment, application programming interfaces, electronic health record integration, and wearable-generated data are expanding how software supports clinical workflows across prevention, diagnosis, treatment, and follow-up. Regulatory expectations are also evolving, with increasing emphasis on quality management systems, software lifecycle documentation, real-world performance monitoring, cybersecurity risk management, and human factors engineering. At the same time, reimbursement and procurement decisions are becoming more evidence-driven, requiring developers to demonstrate clinical utility, workflow fit, health economic value, and equity across diverse patient groups. Interoperability standards, privacy-by-design architecture, and secure data exchange are now strategic requirements rather than technical options. These shifts are creating a more mature SaMD environment in which successful solutions combine validated algorithms, intuitive user experience, regulatory readiness, and measurable clinical outcomes.

Cumulative Impact of Artificial Intelligence on SaMD

Artificial intelligence is amplifying both the opportunities and responsibilities associated with Software as a Medical Device. AI-enabled SaMD can assist in image analysis, risk prediction, triage, remote monitoring, digital therapeutics, disease progression modeling, and personalized clinical recommendations. Its cumulative impact is most visible in the transition from rule-based software to adaptive, data-intensive systems that can identify patterns across multimodal health datasets. However, the use of AI also raises critical requirements for algorithm transparency, dataset representativeness, bias mitigation, clinical validation, explainability, cybersecurity, and ongoing performance monitoring after deployment. Regulators have increasingly focused on predetermined change control, good machine learning practices, and real-world evidence to manage the lifecycle of AI-based medical software. For industry leaders, AI is not simply a feature enhancement; it is a governance challenge that requires cross-functional oversight across clinical science, regulatory affairs, data engineering, ethics, privacy, and quality assurance.

Key Regional Insights for SaMD Adoption

Asia-Pacific is a high-priority region for SaMD adoption due to expanding digital health infrastructure, large patient populations, increasing smartphone penetration, and government-backed healthcare modernization initiatives. Countries across the region are strengthening regulatory frameworks for medical software, while hospitals and payers are exploring remote monitoring, AI-assisted diagnostics, and mobile health tools to address access gaps and specialist shortages. Europe is characterized by rigorous medical device regulation, strong data protection rules, and a focus on interoperability, clinical safety, and conformity assessment under evolving regulatory requirements. North America remains a highly advanced SaMD environment supported by mature digital health adoption, established regulatory pathways, high use of electronic health records, and strong investment in AI-enabled clinical applications, with significant emphasis on clinical evidence, cybersecurity, data privacy, and reimbursement alignment. Latin America is advancing through telehealth expansion, public health digitization, and growing interest in scalable tools for chronic disease management, although infrastructure variability and fragmented reimbursement can affect implementation. Africa presents meaningful long-term potential as mobile-first healthcare, digital public health platforms, and remote consultation tools address workforce and infrastructure constraints, though adoption depends on connectivity, affordability, regulatory capacity, and localized clinical validation. The Middle East is accelerating digital health transformation through national health strategies, hospital modernization, smart city initiatives, and investments in connected care, with SaMD increasingly relevant for remote access, chronic disease monitoring, and digitally enabled specialty care.

Key Group Insights Across Global SaMD Markets

NATO member countries include several advanced digital health systems where cybersecurity resilience, secure cloud infrastructure, and trusted data exchange are especially important due to the sensitivity of healthcare infrastructure and the growing risk of cyber threats targeting medical software ecosystems. G7 countries generally show advanced healthcare IT infrastructure, strong research ecosystems, and heightened expectations for evidence-based digital medicine, including AI governance, privacy protection, and health system integration. BRICS economies represent a broad opportunity set shaped by large populations, rising healthcare digitization, domestic innovation policies, and growing demand for affordable, scalable medical software, while regulatory localization and procurement complexity require country-specific strategies. The European Union is one of the most structured regulatory environments for SaMD, with strong emphasis on medical device conformity, clinical evaluation, post-market surveillance, cybersecurity, and personal data protection, making regulatory planning and evidence generation essential for market entry. ASEAN countries are increasingly important for SaMD as governments promote digital health, cross-border healthcare collaboration, and mobile-first access models, while diverse regulatory maturity across member states creates a need for adaptable compliance strategies. The GCC is advancing SaMD through national digital health programs, hospital digitization, AI adoption, and demand for high-quality care delivery, particularly in chronic disease management, remote patient monitoring, and clinical workflow optimization.

Key Country Insights for Software as a Medical Device

China is rapidly expanding digital health and AI medical software capabilities, supported by large clinical datasets, strong hospital digitization, and evolving regulatory oversight, though data governance and local compliance are decisive. The United States is a leading SaMD environment due to established digital health adoption, active regulatory oversight for medical software, expanding AI-enabled clinical use cases, and increasing attention to cybersecurity and real-world performance. Japan combines advanced healthcare infrastructure, aging population needs, and strong regulatory expectations, creating relevance for SaMD in remote monitoring, diagnostics, rehabilitation, and chronic care. India is gaining momentum through digital public infrastructure, telemedicine adoption, mobile health platforms, and demand for affordable diagnostic and monitoring tools suited to diverse care settings. Germany is shaped by rigorous medical device regulation, digital health reimbursement pathways, strong privacy expectations, and demand for clinically validated digital therapeutics and diagnostic software. The United Kingdom has a strong digital health policy environment, established health technology evaluation mechanisms, and growing focus on AI assurance, clinical safety standards, and integration with national healthcare workflows. Australia supports SaMD adoption through digital health records, telehealth acceptance, privacy regulation, and interest in improving care access across remote and regional communities. France supports SaMD through digital health strategy, reimbursement mechanisms for selected digital medical technologies, and emphasis on clinical evidence, data protection, and healthcare interoperability. South Korea is positioned as an innovation-focused SaMD environment with advanced connectivity, digital hospital capabilities, AI research activity, and regulatory initiatives supporting medical software validation and commercialization. Italy and Spain are advancing adoption through regional healthcare digitization, telehealth expansion, and interest in tools that support chronic disease care, hospital efficiency, and remote monitoring. Canada emphasizes patient safety, health technology assessment, privacy compliance, and equitable access across provincial health systems, supporting demand for validated and interoperable SaMD solutions. Russia's SaMD environment is influenced by domestic digital health modernization, localization priorities, and demand for telemedicine and diagnostic support tools, with regulatory compliance and data governance remaining central. Brazil is one of Latin America's most dynamic digital health environments, supported by large-scale healthcare demand, telemedicine adoption, and regulatory attention to medical software, with opportunities in chronic disease management and remote care. Mexico is advancing through telehealth growth, digital hospital initiatives, and demand for tools that improve access to specialist care, while regulatory navigation and healthcare system fragmentation remain important considerations. Spain benefits from digital health modernization, regional care coordination initiatives, and rising use of telehealth-enabled services, creating demand for secure SaMD solutions that support chronic care, diagnostics, and clinical workflow efficiency.

Actionable Recommendations for SaMD Industry Leaders

Industry leaders should prioritize regulatory strategy early in product development by aligning intended use, risk classification, clinical evaluation, cybersecurity controls, and post-market surveillance with target jurisdiction requirements. SaMD developers should build evidence generation into the product lifecycle, using prospective studies, real-world performance monitoring, usability testing, and health economic analysis to demonstrate clinical value and workflow relevance. AI-enabled SaMD requires robust data governance, bias testing, explainability, model version control, and documented change management to support trust and compliance. Leaders should design for interoperability using recognized health data standards and secure APIs to reduce implementation friction across hospitals, payers, and digital health platforms. Cybersecurity must be treated as a continuous safety requirement, including threat modeling, vulnerability management, secure software development, and incident response readiness. Commercial teams should tailor go-to-market strategies by region, accounting for reimbursement pathways, procurement structures, language localization, clinical practice differences, and data residency requirements. Partnerships with clinicians, health systems, patient groups, and regulators can accelerate validation, adoption, and responsible scaling.

Research Methodology for SaMD Insights

This executive summary is developed through a structured secondary research approach focused on verified, publicly available, and industry-relevant sources. The methodology includes review of regulatory guidance for medical device software, digital health policy documents, clinical safety standards, cybersecurity frameworks, interoperability requirements, health technology assessment materials, peer-reviewed literature, and government publications. Regional, group, and country insights are synthesized by assessing regulatory maturity, healthcare digitization, telehealth adoption, AI governance activity, data protection requirements, cybersecurity readiness, reimbursement mechanisms, and infrastructure readiness. The analysis avoids market sizing, market share, and forecasting and instead focuses on qualitative drivers, adoption dynamics, compliance considerations, and strategic implications. All insights are triangulated across authoritative sources where possible to ensure consistency, relevance, and decision usefulness for stakeholders evaluating Software as a Medical Device opportunities.

Conclusion: The Future of Software as a Medical Device

Software as a Medical Device is becoming a core component of modern healthcare as providers, payers, and patients seek more accessible, intelligent, and continuous care solutions. The sector is advancing through AI-enabled diagnostics, remote monitoring, digital therapeutics, cloud-based workflows, and interoperable clinical decision support, but sustainable success depends on rigorous clinical validation, regulatory compliance, cybersecurity, privacy protection, and post-market oversight. Regional differences in infrastructure, reimbursement, data governance, and regulatory maturity require tailored strategies, while global convergence around safety, effectiveness, transparency, and real-world evidence is raising expectations for all developers. Organizations that combine strong medical evidence, secure engineering, clinician-centered design, and responsible AI governance will be best positioned to deliver trusted SaMD solutions that improve outcomes and strengthen healthcare system resilience.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Software as a Medical Device Market, by Delivery Mode

• 7.1. Introduction
• 7.2. Mobile Based
• 7.3. Standalone
• 7.4. Web Based

8. Software as a Medical Device Market, by Functionality

• 8.1. Introduction
• 8.2. Diagnostic
• 8.3. Monitoring
• 8.4. Prevention
• 8.5. Therapeutic

9. Software as a Medical Device Market, by Risk Classification

• 9.1. Introduction
• 9.2. Class I
• 9.3. Class II
• 9.4. Class III

10. Software as a Medical Device Market, by Data Input Type

• 10.1. Introduction
• 10.2. Medical Imaging
• 10.3. Physiological Signals
• 10.4. Laboratory & Genomic Data
• 10.5. Patient-Reported Outcomes

11. Software as a Medical Device Market, by Therapeutic Area

• 11.1. Introduction
• 11.2. Cardiology
  • 11.2.1. Arrhythmia Monitoring
  • 11.2.2. Blood Pressure Monitoring
  • 11.2.3. Heart Failure Management
• 11.3. Diabetes Management
  • 11.3.1. Glucose Monitoring
  • 11.3.2. Insulin Dosing
  • 11.3.3. Nutritional Management
• 11.4. Neurology
• 11.5. Orthopedic
• 11.6. Respiratory

12. Software as a Medical Device Market, by End User

• 12.1. Introduction
• 12.2. Ambulatory Care
• 12.3. Clinics
• 12.4. Home Care
• 12.5. Hospitals
• 12.6. Clinical Research Organizations

13. Software as a Medical Device Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Software as a Medical Device Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Software as a Medical Device Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AliveCor, Inc.
• 17.3. Baxter International Inc.
• 17.4. Becton, Dickinson and Company
• 17.5. Biotronik SE & Co. KG
• 17.6. Boston Scientific Corporation
• 17.7. Cisco Systems, Inc.
• 17.8. DexCom Inc.
• 17.9. Edwards Lifesciences Corporation
• 17.10. F. Hoffmann-La Roche Ltd.
• 17.11. GE HealthCare Technologies Inc.
• 17.12. Honeywell International Inc.
• 17.13. IBM Corporation
• 17.14. Intel Corporation
• 17.15. Intuitive Surgical, Inc.
• 17.16. iRhythm Technologies, Inc.
• 17.17. Johnson & Johnson
• 17.18. Koninklijke Philips N.V.
• 17.19. Masimo Corporation
• 17.20. Medtronic plc
• 17.21. Microsoft Corporation
• 17.22. Omron Healthcare, Inc.
• 17.23. Oracle Corporation
• 17.24. Qualcomm Life, Inc.
• 17.25. ResMed Inc.
• 17.26. Siemens Healthineers AG
• 17.27. Smith & Nephew plc
• 17.28. Stryker Corporation
• 17.29. Terumo Corporation
• 17.30. Zimmer Biomet Holdings, Inc.